> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Evaluating Symptoms in COPD
- URL: https://www.fdaweb.com/guidance-on-evaluating-symptoms-in-copd/
- Published: 2016-03-09T12:00:00.000Z
- Updated: 2026-09-15T02:42:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135024

*Federal Register* Notice: FDA is making available a draft guidance: *Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome, for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use*. It provides a statement of qualification for exploratory use for evaluating respiratory symptoms in chronic obstructive pulmonary disease, a patient-reported outcome instrument, and summarizes the concept of interest and context of use for which the tool is qualified through the CDER’s drug development tool qualification program. To download this guidance, click [here.](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM489526.pdf?ref=fdaweb.com) To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-09/pdf/2016-05224.pdf?ref=fdaweb.com)